Filtered By:
Condition: Hypertension
Management: Hospitals
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 599 results found since Jan 2013.
Determinants of atrial fibrillation after cardiac surgery
Rev Cardiovasc Med. 2021 Jun 30;22(2):329-341. doi: 10.31083/j.rcm2202040.ABSTRACTPost-operative Atrial fibrillation (POAF) is a common complication post cardiac surgery. It can result in detrimental short- and long-term outcomes due to the increased risk of stroke, cardiac arrest and congestive heart failure in addition to prolonged intensive care and total hospital stay raising the overall healthcare cost. Accurately identifying predictors and biomarkers for POAF ensures that patients at greatest risk can be given the appropriate prophylactic measures; resources can be distributed to the groups who are most in need and w...
Source: Reviews in Cardiovascular Medicine - July 14, 2021 Category: Cardiology Authors: Mashal Qureshi Ammaarah Ahmed Victoria Massie Ellenor Marshall Amer Harky Source Type: research
Evaluation of a package of risk-based pharmaceutical and lifestyle interventions in patients with hypertension and/or diabetes in rural China: A pragmatic cluster randomised controlled trial
by Xiaolin Wei, Zhitong Zhang, Marc K. C. Chong, Joseph P. Hicks, Weiwei Gong, Guanyang Zou, Jieming Zhong, John D. Walley, Ross E. G. Upshur, Min Yu
BackgroundPrimary prevention of cardiovascular disease (CVD) requires adequate control of hypertension and diabetes. We designed and implemented pharmaceutical and healthy lifestyle interventions for patients with diabetes and/or hypertension in rural primary care, and assessed their effectiveness at reducing severe CVD events. Methods and findingsWe used a pragmatic, parallel group, 2-arm, controlled, superiority, cluster trial design. We randomised 67 township hospitals in ...
Source: PLoS Medicine - July 1, 2021 Category: Internal Medicine Authors: Xiaolin Wei Source Type: research
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Adherence to anti-hypertensive medications and its determinants: A study among hypertensive stroke patients in a tertiary care government hospital of West Bengal
Adrija Ray, Tapobrata Guha Ray, Jyotirmoy Pal, Biman Kanti Ray, Debasish Sanyal, Souvik DubeyIndian Journal of Public Health 2021 65(2):198-202
There is a paucity of antihypertensive drug adherence studies among stroke patients in West Bengal. With an aim to identify antihypertensive drug adherence and its determinants, this descriptive cross-sectional study was conducted for 2 months among a calculated sample of 133 study participants using predesigned and pretested schedule, the metric “Proportion of days covered (PDC),” and the Morisky, Green, and Levine (MGL) Scale. Data were compiled and ana...
Source: Indian Journal of Public Health - June 14, 2021 Category: International Medicine & Public Health Authors: Adrija Ray Tapobrata Guha Ray Jyotirmoy Pal Biman Kanti Ray Debasish Sanyal Souvik Dubey Source Type: research
